Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis
Alistair Murray, Tran M Nguyen, Claire E Parker, Brian G. Feagan, John K MacDonald
Abstract
Oral 5-aminosalicylic acid (5-ASA; also known as mesalazine or mesalamine) preparations were intended to avoid the adverse effects of sulfasalazine (SASP) while maintaining its therapeutic benefits. In an earlier version of this review, we found that 5-ASA drugs were more effective than placebo for maintenance of remission of ulcerative colitis (UC), but had a significant therapeutic inferiority relative to SASP. In this version, we have rerun the search to bring the review up to date.
Topics & Concepts
Ulcerative colitisAminosalicylic acidGastroenterologyMedicineInternal medicineColitisDiseaseInflammatory Bowel DiseaseMicroscopic ColitisHelicobacter pylori-related gastroenterology studies